Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 2/20 | 0.31 |
| ▸ | IL1RN | P18510 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967402 | 0.81 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2962692 | 0.79 | ALDH1A1 (0.34) | ALDH1A1MAPK1ANPEPIL1RNERAP2 | |
| SCHEMBL2966230 | 0.77 | AKR1C3 (0.39) | ALDH1A1MAPK1ESR2CYP2A6CYP2B6 | |
| SCHEMBL2958875 | 0.77 | ADRA2A (0.31) | — | |
| SCHEMBL2965788 | 0.76 | ALDH1A1 (0.38) | ALDH1A1MAPK1ESR2PARP10PARP11 | |
| SCHEMBL2976566 | 0.76 | ALDH1A1 (0.38) | ALDH1A1MAPK1ESR2PARP10PARP11 | |
| SCHEMBL2963883 | 0.76 | ALDH1A1 (0.34) | ALDH1A1MAPK1ESR2CYP2A6CYP2B6 | |
| SCHEMBL2963790 | 0.76 | CA12 (0.36) | ALDH1A1CYP2A6 | |
| SCHEMBL2975359 | 0.76 | NISCH (0.40) | ALDH1A1MAPK1 | |
| SCHEMBL2973677 | 0.72 | MEN1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | ALDH1A1 4332/4885MAPK1 3118/4885ESR2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.